<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">MRP</journal-id><journal-title-group><journal-title>Medical Research and Practice</journal-title></journal-title-group><issn>2993-9690</issn><eissn>2993-9704</eissn><publisher><publisher-name>Art and Technology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.61369/MRP.2026060036</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>乳铁蛋白在靶向神经退行性疾病中的研究进展</title><url>https://artdesignp.com/journal/MRP/4/6/10.61369/MRP.2026060036</url><author>张艳禹,王浩男,武明明,王田野,张桐瑞</author><pub-date pub-type="publication-year"><year>2026</year></pub-date><volume>4</volume><issue>6</issue><history><date date-type="pub"><published-time>2026-06-20</published-time></date></history><abstract>神经退行性疾病（Neurodegenerative Diseases, NDDs） 以神经元进行性损伤、丢失及功能障碍为核心特征，伴随铁代谢紊乱、氧化应激、神经炎症、异常蛋白聚集等病理改变，是威胁老年人群健康的重大疾病。乳铁蛋白（Lactoferrin, LF）是一种多功能铁结合糖蛋白，具备穿越血脑屏障、螯合金属离子、抗氧化、抗炎及调控细胞凋亡等多重生物学活性，可通过多靶点、多通路干预神经退行性疾病的病理进程。本文重点阐述其在阿尔茨海默病、帕金森病、肌萎缩侧索硬化等主要神经退行性疾病中的作用机制，总结基于乳铁蛋白的靶向递送系统，展望其在神经退行性疾病防治中的应用前景，为开发新型神经保护药物提供理论依据与研究思路。</abstract><keywords>神经退行性疾病,血脑屏障,铁代谢,氧化应激,神经炎症,靶向递送</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>[1] 赵楠, 蒋瑞, 熊柳林. 乳铁蛋白在中枢神经系统疾病中的作用机制及其研究进展[J]. 中国比较医学杂志, 2023, 33(2): 106‑112.[2] 姚露露, 曹云涛. 乳铁蛋白的神经保护作用[J]. 海南医学, 2018, 29(22): 3189‑3192.[3] Giansanti F, Torosantucci A, Scimeca M, et al. Lactoferrin: a natural glycoprotein involved in inflammation and immunity[J]. Molecules, 2016, 21(10): 1325.[4] 王艳, 李丽, 赵刚. 乳铁蛋白与血脑屏障相互作用的研究进展[J]. 神经解剖学杂志, 2022, 38(4): 478‑482.[5] Zhang Y, Li J, Wang H, et al. Astrocyte‑derived lactoferrin inhibits neuronal ferroptosis by reducing iron content and GPX4 degradation in APP/PS1 transgenic mice[J]. Redox Biology, 2025, 62: 102789.[6] 黄勇, 郑华, 林晓. 乳铁蛋白联合多奈哌齐对阿尔茨海默病患者认知功能的影响[J].中国老年学杂志, 2023, 43(11): 26452648.[7] Xu S, Yan‑Hui Z, S W, et al. Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP‑treated mice[J]. Redox Biology, 2018, 14: 112‑120.[8] Karav S, Eker F, Bolat E, et al. Lactoferrin: neuroprotection against Parkinson&amp;rsquo;s disease and secondary molecule for potential treatment[J]. Frontiers in Aging Neuroscience, 2023, 15: 1204149.[9] 陈明, 周丽, 吴刚. 乳铁蛋白对肌萎缩侧索硬化模型小鼠运动神经元的保护作用[J]. 中国病理生理杂志, 2023, 39(5): 921‑927.[10] Silva M, Costa A, Teixeira J. Lactoferrin as a potential therapeutic agent for multiple sclerosis[J]. International Journal of Molecular Sciences, 2021, 22(15): 8123.[11] 李娟, 王浩, 张宇. 乳铁蛋白靶向递送系统在神经退行性疾病中的应用[J]. 药学学报, 2024, 59(3): 567‑576.[12] Liu X, Chen L, Zhao Y. Lactoferrin‑modified nanocarriers for brain‑targeted drug delivery in Alzheimer&amp;rsquo;s disease[J]. Journal of Drug Targeting, 2022, 30(8): 890‑902.[13] 张伟, 刘敏, 陈静. 重组人乳铁蛋白的制备及生物活性研究[J]. 生物技术通报, 2024, 40(2): 289‑297.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
